Antibody Drug Conjugates (ADC) work by combining a chemotherapy drug with a monoclonal antibody. This allows the chemotherapy drug to target a specific cancer cell while limiting the damage to healthy cells.
A procedure in which a patient receives healthy blood-forming cells (stem cells) to replace their own. The healthy stem cells may come from the blood or bone marrow of the patient, from a donor, or from the umbilical cord blood of a newborn baby.
B-Cell Maturation Antigen (BCMA) is a protein that may be found on the surface of myeloma cells. BCMA may be used as a target to help treatments find and destroy myeloma cells.
A bispecific antibody is a drug that has been designed to simultaneously target two different proteins. Both targets may be expressed by a cancer cell, or these drugs may target both cancer cells and T cells.
BiTEs are a type of immunotherapy. They consist of monoclonal antibodies that can target and bind to both myeloma cells and T Cells.
BET Inhibitors work by blocking chemicals that tell cancer cells to grow.
CAR T Cell therapy is a new way to treat multiple myeloma using your own immune system to target and destroy cancer cells.
Allogeneic CAR T Cell therapy is a new way to treat multiple myeloma using a donor's immune cells to target and destroy cancer cells.
CD48 is a protein that is found on the surface of myeloma cells. This protein may be used as a way for treatments to target and find the myeloma cells.
Checkpoint inhibitors are a type of immunotherapy that works by blocking proteins that stop the immune system from attacking myeloma cells.
Expanded Access (known as Compassionate Use) allows for patients who meet certain requirements to receive drugs that have not yet been approved and that are still undergoing clinical development.
GPRC5D is a protein that may be found on the surface of myeloma cells. This protein may be used as a way for treatments to target (or find) myeloma cells.
Minimal Residual Disease (MRD) is the measurement of very small amounts of myeloma cells that may remain in the bone marrow even after treatment.
Monoclonal antibodies are large, y-shaped, man-made proteins. They are able to target cancer cells by finding and attaching to unique proteins found on the cell's surface.
When the federal government passed the National Cancer Institute Act of 1937, they established standards and guidelines for centers to follow in the areas of research, cancer prevention, and clinical services. To receive designation as an NCI Cancer Center, the facility must have high quality and extensive research and programming in some combination of those areas.
Learn more about observational trials that allow you to participate from the comfort of your own home.
PD-1 is a protein found on the surface of immune cells (called T cells). This protein acts as an "off switch" that may stop your immune system from attacking cancer cells.
Proteasomes are found in all cells. Their job is to get rid of ineffective proteins. Cancerous plasma cells make large amounts of ineffective proteins. A proteasome inhibitor stops the proteasomes from doing their job, allowing the proteins to build up until the cancer cell destroys itself.
Selective Inhibition of Nuclear Export (SINE) is a new treatment classification that can block the export of TSPs (tumor suppressor proteins) and GRPs (growth regulatory proteins) from leaving the myeloma cell. This allows these cancer fighting proteins to remain in the center of the cell (nucleus) to better fight cancer.